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MEETING REPORT
Perspectives in melanoma: meeting report 
from the “Melanoma Bridge” (December 5th–
7th, 2019, Naples, Italy)
Paolo A. Ascierto1* , Igor Puzanov2, Sanjiv S. Agarwala3, Christian Blank4, Richard D. Carvajal5, 
Sandra Demaria6,7, Reinhard Dummer8, Marc Ernstoff9, Soldano Ferrone10, Bernard A. Fox11, 
Thomas F. Gajewski12,13, Claus Garbe14, Patrick Hwu15, Roger S. Lo16, Georgina V. Long17, Jason J. Luke18, 
Iman Osman19, Michael A. Postow20, Ryan J. Sullivan21, Janis M. Taube22, Giorgio Trinchieri23, 
Hassane M. Zarour24, Corrado Caracò25 and Magdalena Thurin26
Abstract 
The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-asso-
ciated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which signif-
icantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and 
tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune 
response. The approval of new immune and targeted therapies has further improved outcomes for patients with 
advanced melanoma and other combination modalities are also being explored such as chemotherapy, radiotherapy, 
electrochemotherapy and surgery. In addition, different strategies of drugs administration including sequential or 
combination treatment are being tested. Approaches to overcome resistance and to potentiate the immune response 
are being developed. Increasing evidence emerges that tissue and blood-based biomarkers can predict the response 
to a therapy. The latest findings in melanoma research, including insights into the tumor microenvironment and new 
biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination 
strategies and the role of neoadjuvant and adjuvant therapy, were the focus of discussions at the Melanoma Bridge 
meeting (5–7 December, 2019, Naples, Italy), which are summarized in this report.
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Introduction
The melanoma treatment landscape changed in 2011 
with the approval of the first anti-cytotoxic T-lympho-
cyte-associated protein (CTLA)-4 checkpoint inhibitor 
and of the first BRAF-targeted monoclonal antibody, 
both of which significantly improved overall survival 
(OS). Since then, improved understanding of the tumor 
microenvironment (TME) and tumor immune-evasion 
mechanisms has resulted in different approaches to tar-
geting and harnessing the host immune response. The 
approval of new immune and targeted therapies has 
further improved outcomes for patients with advanced 
melanoma using various approaches with distinct modes 
of action including single or combination of immuno-
therapy agents, and other combination modalities are 
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electrochemotherapy and surgery. In addition, different 
strategies of drugs administration including sequential 
or combination treatment may potentially be associated 
with clinically relevant improvement of outcome.
However, better understanding of resistance mecha-
nisms and reasons why some patients do not respond, 
or relapse is needed. Treatment strategies in the clini-
cal management of melanoma are evolving in order to 
address these challenges. Approaches to overcome resist-
ance and to potentiate the immune response are being 
developed. Increasing evidence emerges that tissue and 
blood-based biomarkers can predict the response to a 
therapy. Predictive biomarkers can be considered for 
patients stratification or selection of patients who will 
most likely achieve favorable clinical outcome.
The latest findings in melanoma research, includ-
ing insights into the tumor microenvironment and new 
biomarkers, improved understanding of tumor immune 
response and resistance, novel approaches for combina-
tion strategies and the role of neoadjuvant and adjuvant 
therapy, were the focus of discussions at the Melanoma 
Bridge meeting (5–7 December, 2019, Naples, Italy), 
which are summarized in this report.
Melanoma Bridge opening session
Biomarkers for immunotherapy of cancer
The progress in fully realizing the potential of biomarker-
driven assignment for anticancer approaches in immune 
oncology (IO) requires the development and implemen-
tation of novel clinical-grade biomarkers able to guide 
the selection of a single therapy agent or combination 
of drugs with complementary mechanisms of action 
targeting multiple mechanisms of response as well as of 
immune escape.
Biomarkers for immunotherapy require comprehen-
sive approaches that encompass the complexity of the 
immune system and tumor biology which cannot be 
addressed using a single analyte biomarker. Therefore, 
investigation of the biology and genomics of both the 
tumor and the host immune system is critical to recog-
nize potential biomarkers. The availability of novel plat-
forms and technologies should facilitate the integration 
of the molecular features of the tumor and the host fac-
tors for the development of multiplex profiles to guide 
personalized treatment in the future. However, before 
a candidate biomarker and/or new technology can be 
used in a clinical setting, rigorous steps to demonstrate 
the analytical and clinical validity of the biomarkers are 
required. The challenges to overcome include, the inher-
ent complexity of the assays and independent protocols 
that result in high data variability and poor reproducibil-
ity across sites and studies as well as the requirements for 
highly specialized bioinformatics expertise for data inter-
pretation and integration of multi-omics data.
In recognition of these challenges, in 2017 the US 
National Cancer Institute (NCI) at National Institutes 
of Health (NIH) has established the Cancer Immune 
Monitoring and Analysis Centers-Cancer Immunologic 
Data Commons (CIMAC-CIDC) Network. The Network 
is composed of four laboratories (CIMACs) and a bio-
marker data storage/access platform (CIDC), to enable 
systematic analysis and integration of biomarkers associ-
ated immunotherapy clinical trials. The overall goals for 
the CIMAC-CIDC Network are to conduct correlative 
studies focusing on biomarkers of response and resist-
ance in NCI-supported early-phase immunotherapy tri-
als by offering a wide range of validated analyses using 
state-of-the-art methods. The network will also facilitate 
innovative research for new biomarkers, capitalizing on 
recent advances in immune profiling platforms and tech-
nologies, provide centralized bioinformatics resources 
for data collection and integration across trials, and 
establish a biomarker database.
Biomarker assays are categorized at tier one, which are 
broadly recommended for most trials and have harmo-
nized SOPs available across the Network sites including, 
multiplex immunohistochemistry (mIHC) and immu-
nofluorescence (mIF) panels, mass cytometry (CyTOF), 
RNA sequencing, whole exome sequencing and T cell 
receptor (TCR) analysis. Tier two and three assays con-
stitute experimental approaches for which usage depends 
on the specific trial. In 2018, Partnership for Accelerat-
ing Cancer Therapies (PACT) was launched as a public–
private partnership with 12 leading biopharmaceutical 
companies, the NIH, the Food and Drug Administration 
(FDA), and the Foundation for NIH (FNIH). PACT sup-
ports comprehensive immunoprofiling using CIMACs 
validated assays for IO biomarkers for response to treat-
ment in the industry sponsored immunotherapy trials.
Harmonization of laboratory specific protocols with 
SOPs and assay performance benchmarks which is the 
goal of the CIMACs-CIDC Network is necessary to 
overcome variability of methods and data collection in 
both academic and industrial laboratories and enable 
objective interpretation and comparison across differ-
ent studies and multiple sites. Assay harmonization is 
an essential component of developing a biomarker data-
base for secondary analyses to accelerate optimization 
of immunotherapies and the potential success of new 
immunotherapy agents and combinations.
Session—melanoma as a model system
Harnessing the gut microbiome to optimize cancer therapy
The activity of the commensal microbiota significantly 
impacts human health and has been linked to the 
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development of many diseases, including cancer. Recent 
study demonstrated that the composition of the gut 
microbiome can influence the effect of cancer therapy 
by modulating the antitumor immune response efficacy. 
Several recent studies have established that the composi-
tion of the gut microbiome modulates the efficacy of anti-
PD-1 therapy [1–3]. Microbiota taxonomic identification 
in cancer patients may be affected by geography, disease 
and sequencing technology. Moving forward, there is a 
need for a deeper understanding of the underlying bio-
logical mechanisms that link specific bacterial strains to 
host immunity because microbial species associated with 
anti-PD-1 response in different patients are not always 
the same across different cohorts. Integrating microbi-
ome effects with other tumor and host factors regulating 
immunotherapy responsiveness could facilitate optimiza-
tion of therapeutic outcomes.
Even though there is increasing evidence that the 
microbiome has a role in influencing the response to 
therapy, it is not yet known what constitutes a favorable 
microbiome composition or whether gut microbiota can 
be altered to improve therapeutic response. However, 
it opens the exciting possibility to improve efficacy by 
manipulating the gut flora and various strategies to target 
the microbiome have been suggested, including antibi-
otics, probiotics, prebiotics, diet, oral bacterial formula-
tions and fecal microbial transplant (FMT).
FMT approach delivers a fecal microbiota transplant 
(FMT) and the promise to transfer its beneficial effect. 
For example, fecal samples could be prepared from anti-
PD-1 responders that show a favorable composition of 
commensal bacteria, then transplanted endoscopically 
or prepared for oral delivery into patients who are anti-
PD-1-resistant and show an unfavorable composition of 
gut microbes. FMT is being assessed in ongoing trials in 
patients with melanoma who are refractory to anti-PD-1 
treatment. In an ongoing study at the University of Pitts-
burgh, patients who are non-responders to pembroli-
zumab at 12 weeks are receiving FMT from a responder 
patient, with promising preliminary results. An approach 
using “commensal community” approach is a commu-
nity of bacterial strains from healthy human donor feces 
that induces interferon (IFN)-γ-producing CD8 T cells 
improved the therapeutic efficacy of immune checkpoint 
inhibitors in syngeneic tumor models [4] and other trials 
using different consortia are ongoing.
Alternatively, beneficial or immune-potentiating bacte-
ria could be prepared as a probiotics and provided as an 
immunotherapy adjuvant. Another approach is dietary 
intervention. Habitual diet is a key determinant of the gut 
microbiota, and the microbiome composition can be rap-
idly changed by switching from a high-fat, low-fiber diet 
to a low-fat, high-fiber diet or vice versa.
All of these approaches lack the precision to modulate 
very specific bacterial populations and may have variable 
effects depending on the starting state of the commensal 
community. This variability offers research potential and 
requires exploiting the host–microbiome interdepend-
ency to consider for personalized therapy. Future goals 
are the discovery of reliable microbiome-related bio-
markers for prediction of response and stratification of 
patients as well as the identification of favorable micro-
biota for fecal transfer from responder patients or healthy 
donors. Identification of communities of commensal bac-
teria that deliver more potent therapy may be important 
for integrating microbiome effects with other tumor and 
host factors regulating immunotherapy responsiveness 
could facilitate optimization of therapeutic outcomes.
The unsolved issues in treatment of melanoma 
in the adjuvant setting
Since 2015, several adjuvant treatments for resected stage 
III–IV melanoma have been approved. Active adjuvant 
phase III placebo-controlled trials in melanoma include 
the CheckMate-76 study of nivolumab and the KEY-
NOTE-716 study of pembrolizumab, with both studies 
enrolling patients with resected stage IIb/c disease. These 
patients have similar survival rates as patients with stage 
IIIa/b and may benefit from adjuvant therapy.
Implementation of the American Joint Committee on 
Cancer (AJCC) 8th edition staging manual may disrupt 
analyses of active adjuvant clinical trials. It has been 
noted that it is difficult to extrapolate and compare the 
data from one trial to another, complicating interpreta-
tion of current and future trial results in resected stage 
III melanoma [5]. In analysis of the NYU Interdisci-
plinary Melanoma Program Database which staged all 
patients according to AJCC-7 and AJCC-8 guidelines, 
there was significant improvement in prognostic value 
for stage III with addition of the IIID sub-stage. However, 
stage IIC continues to have worse prognosis than IIIA in 
the revised system.
Approval of adjuvant immunotherapies has led to their 
inclusion as standard of care for patients with high-risk 
resected stage III–IV disease. Stage III comprises ~ 23% 
of new cases each year with ~ 21,500 new cases in the 
USA each year. Clinical trials have very strict inclusion 
criteria, but these do not apply to patients treated with 
standard of care in clinical practice so there may be 
higher potential for toxicity in this patient cohort. Stage 
IIB/C patients represent around 10% of new cases, and 
the challenge is to balance clinical benefit with the risk 
of toxicity. Only one in four stage III patients benefit 
from adjuvant therapy [6, 7] and only one in eight stage II 
patients are expected to derive such benefit.
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Although, treatment with combined ipilimumab and 
nivolumab yielded high response rates (RECIST ORR 
73%, pCR 45%) substantial treatment-related adverse 
events (trAEs) (73% grade 3 trAEs) was observed in 
this cohort. Whereas treatment with nivolumab mono-
therapy yielded modest responses (ORR 25%, pCR 25%) 
and low toxicity (8% grade 3 trAEs). Immune correlates 
of response were identified, demonstrating higher lym-
phoid infiltrates in responders to both therapies and a 
more clonal and diverse T cell infiltrate in responders to 
nivolumab monotherapy [8].
Treatment-related factors associated with response 
and toxicity are well characterized, but host factors also 
need to be considered as adjuvant therapy becomes 
more widely available. These include the tumor molecu-
lar features including T cell infiltrate, mutational load, 
gut microbiome, germline genetics, proteomic biomark-
ers and possibly ethnicity. Composition and abundance 
of the gut microbiome was shown to be associated with 
immune checkpoint inhibitor response [9]. Two autoim-
mune germline variants as potential biomarkers of anti-
CTLA4 or anti-PD1 immune checkpoint inhibitors (ICI) 
efficacy in melanoma were identified and suggests that 
underlying genetic susceptibility to autoimmunity may 
play an important role during ICI treatments. rs1893217 
in PTPN2, involved in cytokine signaling, has been asso-
ciated with colitis, celiac disease, inflammatory bowel, 
rheumatoid arthritis and type 1 diabetes. Similarly, 
rs17388568 was mapped to important immune-related 
genes (IL-2, IL-21 and ADAD1) and associated with 
allergy, colitis and type 1 diabetes [10]. Ongoing research 
focused on predicting response and toxicity emphasizes 
the need for additional studies to optimize treatment reg-
imens and to validate putative biomarkers that will allow 
patient selection for adjuvant immunotherapy, an impor-
tant consideration as the number of patients receiving it 
as a standard of care increases.
Emerging targets in the tumor microenvironment 
to improve radiotherapy and immunotherapy 
combinations
Increasing the numbers and activation of a specific 
dendritic cell (DC) subset, conventional type 1 DCs 
(cDC1s), in tumors can potentially increase the respon-
siveness of cancer patients to immunotherapy. cDC1s 
initiate de novo T cell responses after migrating to 
tumor-draining lymph nodes, as well as recruiting 
T cells, secreting cytokines e.g. IL-12, and present-
ing tumor antigens in the tumor microenvironment 
(TME) (PMID: 30352680). Radiation therapy mediates 
antineoplastic effects not only by cytotoxic and cyto-
static mechanisms, but also by modulating both local 
and systemic immunological function. However, the 
mechanisms by which radiation induces antitumor T 
cells remain unclear. Radiation therapy activates a viral 
defense response pathway, in which cytosolic DNA 
stimulates secretion of IFN-β by cancer cells following 
activation of the DNA sensor cGAS and its downstream 
effector stimulator of interferon genes (STING). Repeat 
irradiation at doses that induce optimal cytosolic DNA 
accumulation amplifies IFN-β production, resulting in 
recruitment and activation of cDC1s, also known as 
Batf3-dependent DCs, which are essential for priming 
of CD8+ T cells that mediate systemic tumor rejec-
tion (the abscopal effect). However, epigenetic down-
regulation of cGAs and/or STING in some tumors 
may preclude the activation of IFN type I by radiation 
therapy (REF: PMID: 29367762). We have recently 
identified an alternative pathway for the recruitment 
and activation of cDC1 to irradiated tumors. The bal-
ance between pro-inflammatory NAD+ and ATP and 
immunosuppressive adenosine in the TME regulates 
immune responses, with the accumulation of extracel-
lular adenosine a strategy used by tumors to escape 
immunosurveillance [11]. CD73 is an ecto-5-nucleoti-
dase that is essential for the generation of extracellular 
adenosine from 5-adenosine monophosphate (5-AMP). 
CD73 is the final enzyme for both the canonical and 
non-canonical adenosine generation pathways In the 
canonical pathway CD39 (ecto-nucleoside triphosphate 
diphosphohydrolase-1; ecto-NTPDase1) catalyzes the 
phospho hydrolysis of ATP and ADP to AMP. In the 
non-canonical pathway, CD38 catalyzes the conver-
sion of NAD+ to ADPR and CD203a converts ADPR 
to AMP (PMID: 27209048). Radiation-induced cell 
death is associated with release of ATP and NAD+ in 
the TME, but we found that radiation also induces the 
upregulation of CD38, CD203a and CD73 on cancer 
cells. Antibody-mediated blockade or genetic knock-
down of CD73 restored the recruitment and activa-
tion of cDC1 to irradiated tumors that lacked cGAS 
expression and were unable to produce IFNγ (PMID: 
32047024). CD73 blockade led to increased infiltration 
and activation of CD8+ T cells and decreased regula-
tory T cells (Treg) in the tumor, associated with com-
plete tumor regression during dual CD73 and CTLA-4 
blockade in combination with irradiation.
Thus, CD73 acts as immune checkpoint that precludes 
radiation-induced anti-tumor T cell activation. High 
levels of soluble CD73 at baseline have been associated 
with poor OS and PFS in metastatic melanoma patients 
treated with nivolumab [12]. Blocking CD73-dependent 
adenosine-mediated immunosuppression may have the 
potential to reinstate anti-tumor immunity and synergize 
with radiotherapy and immune checkpoint blockade to 
improve tumor control in patients.
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Immunotherapy‑induced anti‑cancer responses 
to the spectrum of “Cancer Antigens” and immune 
contraction
For over 30  years, immune responses against shared 
cancer antigens have provided evidence of therapeutic 
activity in preclinical and clinical studies. There is a coor-
dinated B and T cell response to cancer and evidence that 
IgG responses can correlate with CD8 T cell response. 
Observations have indicated that circulating cytotoxic 
T lymphocytes (CTLs) can recognize and eliminate lung 
cancer cells presenting endogenous non-mutated pep-
tides [13]. Specifically, they demonstrated that NSCLC 
patients’ sera were found to have IgG antibodies to doz-
ens of proteins from which peptides that were presented 
on HLA by the NSCLC tumor cells originate. They show 
that patients could mount a cytotoxic lymphocyte (CTL) 
response to nonmutated peptides from the same proteins 
that were the target of IgG responses, and that these CTL 
could lyse an HLA-matched allogeneic NSCLC.
These and other data suggest patients have broad anti-
cancer immunity against self-non-mutated epitopes 
and that IgG antibodies identify targets of CD8 T cell 
response. It is possible that once ‘re-activated’ with anti-
gen and cytokine, T cells can kill cancer cells.
Correlation between increased CD8+ T cell IFN-γ 
release and serum IgG binding was also demonstrated 
by a study in which female BALB/c mice were vaccinated 
with a combination of an autophagosome-enriched vac-
cine derived from 4T1 mammary carcinoma along with 
poly-I:C adjuvant where serum was screened for IgG 
binding to arrays of peptides containing known muta-
tion sites in 4T1 [14]. Simultaneously, CD8+ T cell cul-
tures were primed with peptides derived from these 
antigens. These primed T cells were then stimulated to 
measure recognition of the peptides or live 4T1 cells by 
IFN-γ release. Vaccinated mice showed elevated anti-
gen specific CD8+ T cell recognition of 4T1 tumor cells 
and CD8 specific peptides. Antibodies had stronger 
recognition of neoantigens peptides than autoantigens 
counterpart peptides which differ by a single amino acid 
substitution, suggesting a bias for the recognition of cer-
tain antigens prior to tumor exposure, which may be 
due to the tolerance to autoantigens or prior exposure 
to cross-reactive foreign antigens. There was a correla-
tion between increased CD8+ T cell IFN-γ release and 
serum IgG binding to individual peptide antigens. These 
reports suggest that antibody immunosurveillance is 
occurring in early in cancer patients and that IgG anti-
body responses can be used to identify proteins that 
are targeted by T-cell responses. Potentially, the ben-
efits of immune checkpoint blockade may be restricted 
to tumors with pre-existing immune recognition, thus 
evaluation of immune status may serve as a biomarker for 
personalization of immuno-therapy. Furthermore, lack of 
pre-existing immune response should identify patients 
for de novo boosting immune response including vac-
cination or combination with other agents that might 
improve therapeutic efficacy. The DRibbles vaccine is 
comprised of autophagosome vesicles that contains more 
than 100 shared cancer antigens. The effect of vaccina-
tion with the first allogeneic human DRibbles vaccine, 
DPV-001, on IgG responses to proteins overexpressed 
by many/most cancers is being assessed with promising 
results.
The role of melanoma derived exosome in modifying 
the tumor microenvironment
Exosomes are members of the extracellular vesicle com-
munity including micro vesicles and oncosomes that 
originate from multivesicular bodies and that contain 
proteins, mRNA, microRNA and DNA and are enriched 
in tetraspanins, i.e. proteins containing four transmem-
brane domains. Exosomes are cell-derived nano-meter 
sized (40–100 nm) particles that have been established to 
play an important role in cell-to-cell communication [15]. 
Tumor derived exosomes (TEX) have profound impact 
on the immediate tumor microenvironment (TME) and 
they can play a role at distant tissue sites to create a pre-
metastatic niche conducive to metastasis and are referred 
as the tumor “macroenvironment” (TMaE). TEX deliver 
tolerogenic signals to immune cells, inhibiting immune 
cell proliferation, inducing apoptosis of activated CD8+ 
T lymphocytes, interfering with monocyte differentia-
tion and promoting the expansion of regulatory T cells 
thus inducing immune suppression through a paracrine 
effect. Interestingly, TEX display certain ligands, such 
as programmed death-ligand 1 (PD-L1), to produce an 
endocrine signaling effect to generate a favorable pre-
metastatic TMaE extending a distance away from the pri-
mary tumor.
Exosomes have been widely studied in the recent years 
as they were discovered to be a mechanism by which 
tumor cells enhance progression and metastasis. We 
have demonstrated that one pathway in creating a pre-
metastatic niche is through TEX metabolically repro-
gramming normal fibroblasts and generating an acidic 
microenvironment detrimental to immune function. 
HMEX can reprogram the metabolism of normal stromal 
fibroblasts by skewing the dominant metabolic process 
from OXPHOS to aerobic glycolysis, encompassing the 
Warburg effect and inducing extracellular acidification 
that has been shown to contribute to a pre-metastatic 
niche and a state of anergy of CD8+ T lymphocytes. 
Other pathways include direct engagement of TEX with 
receptors on immune cells as they express ligands that 
engage receptors on T cells, including the T cell receptor 
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(TCR) and IL-2 receptor (IL-2R) on T cells. TEX PD-L1 
can suppress T cell activation and enhance tumor spe-
cific immune suppression. TEX inhibit the IL-2 prolif-
erative response in CD8+ T cells and favor regulatory T 
cell responses. TEX can also suppress monocyte matu-
ration and generate a monocytic myeloid-derived sup-
pressor cell phenotype (Mo-MDSC) that is favorable to 
tumor escape from immune recognition. TEX may also 
promote a pre-metastatic niche at a distant site through 
blood and lymphatic drainage to promote vascular per-
meability, immunosuppression and metastasis. Exosome 
distribution through the vascular and lymphatic systems 
can allow TEX to enhance the TMaE beyond the imme-
diate TME, extending the seed and soil hypothesis by 
concluding that the soil may be prepared prior to seed-
ing via cancer exosomes and their miRNA and protein 
payloads. There, TEX act on normal stroma fibroblasts by 
translocation of growth factor receptors and metabolic 
reprogramming using microRNA payloads, promoting 
a switch from oxidative phosphorylation (OXPHOS) to 
aerobic glycolysis and an increase in extracellular acidifi-
cation that contribute to the anergy of CD8+ T cells [16].
TEX are important messengers that enhance tumori-
genesis and metastasis. They achieve this through a vari-
ety of mechanisms including immunosuppression, and 
molecular and metabolic reprogramming that create a 
pre-metastatic niche to facilitate the process of tumor 
progression. Studies have shown that TEX not only influ-
ence the immediate TME, but they also travel to distant 
tissue sites to establish a host-tumor “macroenviron-
ment” through an endocrine phenomenon.
Low‑dose radiation and CAR T cell‑mediated in vitro 
elimination of melanoma cells
A rapidly emerging immunotherapy approach called 
adoptive cell transfer (ACT) is based on collecting and 
using patients’ own immune cells to treat their cancer. 
There are several types of ACT: TILs, TCRs, and CARs, 
but, thus far,  the one that has advanced the furthest in 
clinical development is called chimeric antigen receptor 
(CAR) T-cell therapy. The selection of appropriate target 
antigens in solid tumors remains challenging for the ther-
apeutic development of safe and effective CAR-T-based 
therapies. The high expression of B7-H3 and chondroitin 
sulfate proteoglycan 4 (CSPG4) across multiple tumor 
types such as prostate, breast, placenta, liver, colon, and 
lymphoid organs and restricted expression in normal tis-
sues makes them attractive targets for immunotherapy. 
CSPG4 is a cell surface type I transmembrane protein 
critical for tumor progression and metastasis. B7-H3 
(CD276) is an immune checkpoint from the B7 family of 
ligands, many of whom interact with known checkpoint 
markers including CTLA-4, PD-1, and CD28 and it is 
overexpressed in many cancer types.
Besides identification of a suitable tumor associated 
antigen (TAA), trafficking of administered CAR T cells 
to the tumor is another challenge to effective therapy. In 
addition to the limited trafficking of CAR T cells to solid 
tumors the mechanisms of resistance against CAR T 
cell mediated killing includes immunosuppressive TME. 
Consequently, experimental models to improve innate 
CAR T cell trafficking via coexpression of chemokine 
receptors have been developed. Therapeutic activity 
of CAR-Ts can also be limited due to the rapid tumor 
escape when the targeted antigen shows heterogene-
ous expression within the tumor, as recently reported in 
patients with glioblastoma treated with CAR-Ts specific 
for EGFRVIII. Increasing evidence suggests that intrin-
sic characteristics of CAR molecules, such as the epitope 
recognized by the CAR and the affinity of the mAb from 
which the CAR is derived, may play a significant role in 
discriminating antigen recognition in normal versus 
malignant cells.
BRAF mutation has been shown to downregulate 
HLA class I and tumor antigen expression on melanoma 
cells. Radiation upregulated B7-H3 and CSPG4 expres-
sion on BRAF wild type human MV3 melanoma cells 
treated with a BRAF inhibitor. In BRAF-mutated human 
M21 melanoma cells, radiation induced B7-H3 level but 
there was limited modulation of CSPG4. Radiation also 
upregulates HLA-A/B/C on human M21 melanoma 
cells. Radiation seems to have a higher effect on BRAF 
inhibitor-resistant cells compared to their BRAF inhi-
bition-sensitive counterparts in terms of tumor antigen 
upregulation and modulation of pro- and anti-apoptotic 
molecules. Radiation upregulated B7-H3 expression on 
human M21-R melanoma cells, resistant to BRAF inhibi-
tors. In addition there was differential in vitro elimination 
of both BRAF inhibitor sensitive and resistant melanoma 
cells by B7-H3- or CSPG4-specific CAR T cells.
Radiation can render melanoma cells more sensitive to 
CAR T cell-mediated lysis through upregulation of the 
targeted tumor antigen, and imbalance between pro- and 
anti-apoptotic molecules. At high effector to target cell 
(E:T) ratio, there is no difference in terms of the cyto-
toxic effect of CAR T cells against BRAF inhibitor sensi-
tive and resistant melanoma cells. However, at lower E:T 
ratio, CAR T cells demonstrate more potent in vitro anti-
tumor activity with irradiated BRAF inhibitor resistant 
melanoma cells.
These data not only support the potential of achiev-
ing clinical benefits using CAR T cells in solid tumors 
but also highlight that their antitumor activity can be 
enhanced by radiation of target tumor cells.
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The model system for understanding checkpoint inhibitor 
resistance in cancer
Immune checkpoint inhibitors have revolutionized 
the treatment of patients with advanced-stage meta-
static melanoma, as well as patients with many other 
solid cancers, yielding long-lasting responses and 
improved survival. However, a subset of patients who 
initially respond to immunotherapy, later relapse and 
develop therapy resistance (termed “acquired resist-
ance”), whereas others do not respond at all (termed 
“primary resistance”). Primary and acquired resistance 
are key clinical barriers to further improving outcomes 
of patients with metastatic melanoma, and the known 
mechanisms underlying each involves various com-
ponents of the cancer immune cycle, and interactions 
between multiple signaling molecules and pathways.
Although there is a large body of literature on 
response, the specific mechanisms of resistance and 
biomarkers of resistance have not been well studied. 
Overcoming therapy resistance requires a thorough 
understanding of the mechanisms underlying immune 
evasion by tumors. For an immunotherapy to elicit 
an efficient antitumor immune response, the cancer 
immune cycle must be initiated, and the subsequent 
steps successfully completed. This involves efficient (i) 
antigen presentation and T-cell activation, (ii) T-cell 
trafficking and tumor infiltration, and (iii) T-cell killing 
activity within the tumor microenvironment.
Studies examining possible predictive biomark-
ers of response to immunotherapy have reported a 
higher density of preexisting cytotoxic T lymphocytes 
in tumor biopsies of patients who displayed a greater 
response to anti-PD-1/PD-L1 immunotherapy, and 
more significantly, an increased influx of T cells and 
PD-L1 macrophages early during treatment.
Patients with advanced melanoma with a favorable 
prognosis tend to be those with low volume disease, 
normal baseline LDH and a low number of meta-
static sites. Tumors with high tumor mutation burden 
(TMB) and high IFN-γ-gene expression profile (GEP) 
both exhibit independent predictive value for response 
to anti-PD-1 therapy, and represents the best tissue-
related predictive tool to date, although not clini-
cally validated in prospective trials [17]. The analysis 
of tumors across 22 tumor types including melanoma 
from 4 KEYNOTE clinical trials showed that TMB and 
inflammatory biomarkers (T cell-inflamed GEP and 
PD-L1 expression) can jointly stratify human cancers 
into groups with different clinical responses to pem-
brolizumab monotherapy. With this stratification in 
mind, we can identify patterns of underlying, targetable 
biology related to these groups. TMB and inflammatory 
biomarkers independently predict response and may 
capture distinct features of neo antigens presence and 
T cell activation, respectively.
Comprehensive clinical and genomic analysis demon-
strated that TMB and IFN-γ expression independently 
predicted response in 77 melanoma patients treated with 
anti-PD-1 monotherapy or combined with ipilimumab 
[18]. However, several patients did not fit this pattern as 
they either responded despite having low TMB and IFN-γ 
or had high TMB and IFN-γ but did not respond. These 
patients are of particular interest in terms of understand-
ing possible mechanisms of resistance.
In the clinic, patients who progress can be categorized 
into four distinct primary progression groups: homo-
geneous and generalized with no benefit from therapy 
(more common with immunotherapy than targeted 
therapy), primary progression that is heterogenous and 
solitary/oligometastatic, secondary progression after 
an initial response (i.e. acquired resistance) that is het-
erogenous and solitary/oligometastatic, and secondary 
progression that is homogeneous and generalized (more 
common with targeted therapy). These clinical defini-
tions can be used in prognostic models.
The resistance occurs when there is failure to induce an 
effective antitumor immune response, as demonstrated 
by primary or acquired resistance to immunotherapy in 
melanoma. These two types of resistance are character-
ized by several molecular features.
1. Primary resistance patients have elevated levels of 
baseline serum LDH, low tumor burden and lack of 
PD-L1 expression in baseline melanoma tissue sam-
ples, lack of T-cell infiltration, the absence of PD-1 T 
cells and PD-L1 macrophages in melanoma biopsies 
taken early during treatments, insufficient neoanti-
gens and low mutational burden, the presence of an 
innate anti-PD-1 (IPRES) transcriptional resistance 
signature, or absence of an interferon signature.
2. Acquired resistance occurs in patients who relapse 
after exhibiting an initial response to immunotherapy. 
An example of one such trait is beta-2-microglobulin 
(B2M), a component of MHC class I molecules that is 
necessary for their functional expression. The loss of 
B2M expression was reported in melanoma cell lines 
from five patients who had been treated with immu-
notherapy and cytokine-gene therapy. This resulted 
in a loss of MHC class I expression and, therefore, a 
subsequent decrease in recognition by CD8þ T cells. 
JAK1/2 mutations have also recently been identi-
fied as genetic markers of acquired resistance to 
immunotherapy in melanoma that is responsible 
for cell proliferation, differentiation, cell migration, 
and apoptosis. Other immune checkpoint markers 
such as lymphocyte activation gene 3 (LAG-3) and 
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T-cell immunoglobulin and mucin domain 3 (TIM-3, 
HAVCR2) have also been revealed to interfere with 
the activity of T cells, resulting in acquired resistance 
to immunotherapy.
The research approach for molecular characterization 
of underlying mechanism of resistance requires analysis 
of biopsies at baseline, early during treatment and at dis-
ease progression. However, challenges in using advanced 
melanoma as a model include heterogeneity of tumors, 
with samples enriched for subcutaneous and lymph 
nodes and limited sampling of other sites, quality issues 
in sampling of metastases. An alternative model that 
offers the advantages of abundant is homogenous resist-
ant tumor tissue from neo-adjuvant trials. Several trials 
are ongoing in the neoadjuvant setting with to provide 
high quality matched clinical data and clear endpoints, 
with the primary endpoint of pathological complete 
response (CR) closely correlated with the secondary end-
point of long-term recurrence-free survival (RFS) [19].
Electrochemotherapy in integrated approach of metastatic 
cutaneous melanoma
Electrochemotherapy (ECT) is an electroporation (EP)-
based technology used for clinical application and 
research that includes drug delivery. Specifically, ECT is 
a local and nonthermal tumor ablation modality, which 
combines the administration of a poorly permeant cyto-
toxic agent with the local application of electric pulses 
that induce reversible EP, thus improving drug diffusion 
into the cells. ECT is performed using either intratu-
moral or intravenous cytotoxic drug injection, followed 
by the application of electric pulses locally delivered to 
the target tumor. ECT can be used when surgery is not 
an option. ECT has comparable or superior effectiveness 
over several ablative skin-directed therapies such as over 
photodynamic therapy, radiotherapy, intralesional ther-
apy, and topical therapy. Also, it can be used for chemo-
therapy-resistant and radiotherapy-resistant lesions. ECT 
is suitable for patients with severe comorbidity and/or 
patients of an advanced age who have already exhausted 
all other treatments. Indications for its use in melanoma 
include early cutaneous relapse after surgical treatment 
and effective treatment of tumor lesions located in the 
skin or subcutaneous tissue, both primary and meta-
static. It has also shown its effectiveness in the case of 
treating deep-seated tumors. ECT can be also used as 
an alternative approach or as a palliative treatment after 
standard therapies (such as surgery, radiotherapy, and 
chemotherapy) to improve the quality of life for patients, 
and as neoadjuvant therapy for extensive lesions or to 
reduce the surgical approach. ECT can provide long-
term benefit in terms of curative and palliative treatment 
for unresectable cutaneous lesions [20]. In a prospective 
study of 376 patients with superficial metastases, tumor 
response rate at 60  days was 88% (50% CRs) [21]. ECT 
was also shown to be a highly effective local treatment 
for melanoma metastases in the skin in an International 
Network for Sharing Practices on Electrochemotherapy 
(InspECT) trial that reported an objective response rate 
(ORR) of 74%, 1-year OS of 67% and MSS of 74% [22]. 
Treatment was well tolerated with no serious adverse 
events. Coverage of deep margins, previous irradiation of 
the treated area and tumor size (< 3 cm) were positively 
associated with a CR.
As with radiotherapy, ECT may induce an absco-
pal effect which suggests the potential for combining 
with immunotherapy. This may result from releasing of 
tumor antigens due to ECT treatment and induction of 
inflammatory response, cytokine production, comple-
ment activation, increased MHC class I expression and 
T cell activation resulting from checkpoint inhibition. 
Retrospective analysis of 15 patients treated with ipili-
mumab who received ECT reported a local ORR of 67% 
of patients (27% CR and a systemic response in 60% of 
patients [23]. Evaluation of circulating regulatory T cells 
(Tregs) demonstrated significant differences between 
responders and non-responders. Overall, treatment was 
well-tolerated. In 127 melanoma patients treated with 
ipilimumab, the combination with local peripheral treat-
ment (local irradiation, skin directed ECT or selective 
internal radiotherapy of liver metastases) significantly 
prolonged OS (93 vs. 42  weeks with ipilimumab alone) 
[24]. Immune-related toxicities were not increased by 
the combination and local peripheral treatment-induced 
local toxicities were mostly mild. Overall, ECT appears to 
be feasible and tolerable, with potent anti-tumor activity 
and a high response rate, and the potential for use with 
immunotherapy.
ECT is used currently for treatment of cutaneous and 
subcutaneous lesions, without consideration of their his-
tology. It is also becoming a practical method for treat-
ment of internal, deep-seated tumors and tissues.
New perspectives in uveal melanoma
Uveal melanoma (UM), a rare subset of melanoma, is 
the most common primary intraocular malignancy in 
adults. Despite effective primary therapy, nearly 50% 
of patients will develop metastatic disease. Outcomes 
for those with metastatic disease remain dismal due to 
a lack of effective therapies. Current immunotherapies 
are less effective in UM than cutaneous melanoma. A 
meta-analysis in patients with metastatic uveal mela-
noma treated with anti-PD-1/PD-L1s reported an ORR 
of only 3.6% and a median PFS of 2.6 months [25]. These 
poor results were confirmed in another meta-analysis, 
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which showed a median PFS of 2.8 months in patients 
receiving immunotherapy [26]. Results of single-agent 
checkpoint blockade for UM have generally been dis-
appointing. Dual checkpoint blockade with ipilimumab 
and nivolumab in combination has achieved numeri-
cally superior outcomes to checkpoint blockade mono-
therapy; however, outcomes were still comparatively 
poor. In a phase II, single-arm trial in 50 patients 
with untreated metastatic UM, ORR was 12%, median 
PFS 3.3  months and median OS 12.7  months [27]. 
Treatment-related adverse events were reported in 46 
patients and nine patients discontinued treatment.
The differential response to checkpoint blockade 
between uveal and cutaneous melanoma may, in part, 
it can be explained by the unique biology and immu-
nology of uveal melanoma that necessitates the devel-
opment of dedicated management and treatment 
approaches. The vast majority (85–95%) of uveal mela-
noma is characterized by activating mutations in genes 
encoding the G-protein-alpha subunits GNAQ or 
GNA11, which lead to stimulation of the MAPK and 
phosphatidylinositol 3-kinase (PI3K)/Akt pathways. 
Several other genetic alterations have been implicated 
in the development of uveal melanoma. Inactivating 
mutations in BAP1, a tumor suppressor gene located 
on chromosome 3p, are found in approximately 47% 
of primary uveal melanoma and 84% of metastatic 
uveal melanoma cases, consistent with the association 
between BAP1 mutations and poor prognosis. Muta-
tions in splicing factor 3B subunit 1 (SF3B1), involved 
in pre-messenger RNA splicing, while associated with 
more favorable prognostic features than BAP1 muta-
tions, are also found in cases of delayed metastasis, 
with a median of 8.2 years. EIF1AX encodes for eukary-
otic translation initiation factor 1A. These mutations 
are mutually exclusive from BAP1 and SF3B1 and are 
associated with a longer disease-free survival and a 
more favorable prognosis
Furthermore, metastatic UM are characterized by the 
low mutational burden observed in uveal melanoma may 
partly account for the limited success of immune check-
point blockade. Moreover, upregulation of immunosup-
pressive factors such as Indoleamine 2,3-dioxygenase 
(IDO1) and T cell immunoreceptor with Ig and ITIM 
domains (TIGIT) may contribute to treatment resistance 
and suggests a role for combination immune therapies 
targeting these additional factors. There is a significant 
decrease in PD-1-positive lymphocytes and lower lev-
els of PD-L1 in metastatic uveal melanoma compared 
with cutaneous melanoma metastases. Tumors from 
metastatic UM patients also show a lower rate of tumor-
infiltrating lymphocyte (TIL) expansion compared with 
metastatic cutaneous melanoma [28].
However, while uveal and cutaneous melanoma diverge 
in many features, phenotypic commonalities such as 
expression of the melanoma-associated antigen gp100 
remain. Data from The Cancer Genome Atlas (TCGA) 
show that transcript expression of gp100 is observed 
in both with more uniformly high expression of gp100 
transcript in primary uveal melanoma compared with 
compared primary cutaneous melanoma. Tebentafusp 
(IMCgp100) is a bispecific biologic in development by 
Immunocore, comprising targeting and effector moie-
ties. The targeting end constitutes a soluble T cell recep-
tor (TCR) that recognized the melanocyte-associated 
antigen glycoprotein 100 (gp100) presented in the con-
text of HLA-A2, which is expressed in approximately 
50% of patients with uveal melanoma, and the effector 
end includes an anti-CD3 single chain variable frag-
ment (scFv). In  vitro, IMCgp100 redirects a potent T 
cell-mediated immune response toward gp100 positive 
melanoma cells. In a phase I trial, 3/17 (18%) patients 
with metastatic uveal melanoma achieved a PR and 11/17 
(65%) achieved disease control for ≥ 16 weeks. OS rates 
at 1 year of 74% (95% CI 48–88) were also achieved [29]. 
Two potential explanations for the apparent beneficial 
effect of tebentafusp in uveal melanoma are that gp100 
expression is particularly high in this tumor type and that 
recruiting T cells to antigen-positive sites and inducing 
an inflammatory response in the presence of a relatively 
non-T cell-inflamed genetic signature might help over-
come this barrier. The therapeutic advances that have 
translated to improved patient survival in cutaneous 
melanoma have unfortunately not yielded similar ben-
efits in advanced uveal melanoma. However, ongoing 
efforts seek to optimize the efficacy of targeted therapy 
and immunotherapy in both the adjuvant and metastatic 
setting.
Session—mechanism of resistance and drivers 
of response
Translational research in the metastatic melanoma: recent 
results
Cell invasion through the basement membranes is cru-
cial during morphogenesis and cancer metastasis. The 
basement membrane is a dense, highly cross-linked, 
sheet-like extracellular matrix that underlies all epithe-
lia and endothelia. During development of metastatic 
disease, cells cross the basement membrane to disperse 
and enter new tissues. This complex invasive process 
depends on a coordinated network of polarization, the 
production of matrix metalloproteinases, breaching of 
the basal membrane and the formation of invadopodia-
like structures. The transmembrane migration of cancer 
cells recapitulates the penetration of epithelial cells dur-
ing development.
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Models to study basal membrane breaching include 
chick chorioallantoic membrane, drosophila imaginal 
discs, studies of leukocyte transmigration in vertebrates 
and intravital imaging studies in murine tumor models 
and anchor cell invasion in the nematode Caenorhabditis 
elegans. Anchor-cell invasion in C. elegans is a simple and 
attractive model of regulated cell-invasive behavior.
Importantly, the pre-replication complex including 
cyclin-dependent kinase CDKN2A is an essential compo-
nent during basal membrane disruption. Several compo-
nents of the DNA pre-replication complex are required 
for anchor cell invasion. Three genes required for nor-
mal anchor cell invasion encode cell cycle regulators: 
cell division cycle 6 (CDC6) ATP binding protein is an 
essential component of the DNA pre-replication com-
plex, CYD-1 encodes the only cyclin D homolog in C. ele-
gans and cyclin-dependent kinase 12 (CDK12) encodes 
the CDK required for activation of RNA polymerase II. 
The pre-replication complex controls actomyosin polar-
ity and pro-invasive gene expression in the G1-arrested 
anchor cell.
The acquisition of invasive behavior also marks a criti-
cal transition during melanoma progression [30]. The 
study provides direct evidence that this ability is pro-
moted by increased cellular motility and migration of 
neoplastic melanocytes from the epidermis into the sub-
jacent dermis that results from CDKN2A loss. The most 
common acquired genetic change distinguishing precur-
sor lesions, such as melanocytic nevi or melanoma in situ 
(MIS), from invasive melanomas is loss of the CDKN2A 
locus. The CDKN2A locus encodes two gene prod-
ucts—p14ARF and p16INK4A—each under transcrip-
tional regulation by independent promoters and each 
with distinct tumor suppressive functions. The loss of 
p16INK4A promotes melanocyte motility and the inva-
sive and metastatic capacity of melanoma cells through 
the transcriptional activation of BRN2, a transcription 
factor previously associated with melanocytic invasive 
programs during both development and disease was 
demonstrated [31]. Loss of p16INK4A promotes melano-
cyte motility and the invasive and metastatic capacity of 
melanoma cells through the transcriptional activation of 
BRN2, a transcription factor previously associated with 
melanocytic invasive programs during both development 
and disease. Targeting of the pre-replication complex is a 
promising approach for chemoprevention of melanomas 
and other cancers.
Intrinsic tumor genomic and metabolic factors leading 
to immunoresistance
Significant progress has been made in the field of can-
cer immunotherapy however, durable responses are only 
achieved in a subset of patients, and currently there is 
very limited ability to predict whether a patient is likely 
to respond to immunotherapy. Recently, several studies 
have elucidated some of the tumor intrinsic molecular 
mechanisms of resistance to immunotherapy. Tumors 
use various mechanisms to evade the immune system 
that involve avoiding detection, promoting an immuno-
suppressive microenvironment, and resisting cell death. 
For example, tumor cells can avoid detection through 
B2M loss and class I down regulation (Fig. 1).
RNA-binding protein MEX3B was identified as a can-
didate protein whose overexpression in melanoma cells 
decreased their susceptibility to killing by autologous TIL 
in  vitro suggesting that it  mediates resistance to cancer 
immunotherapy. Overexpression of MEX3B in mela-
noma cells decreased IFN-γ release by autologous TILs 
and downregulated HLA-A expression [32]. Downregu-
lation of HLA-A expression by MEX3B is a novel mecha-
nism for tumor cells to evade attack by T cells. Analysis 
of anti-PD-1 treated melanoma patient tumor samples 
suggested that higher MEX3B expression is associated 
with resistance. Our findings have the potential to lead 
to the development of therapeutic strategies targeting 
MEX3B in hope of overcoming immunoresistance and 
achieving better clinical outcomes for patients with mela-
noma treated with immunotherapy.
Tumor cells can also produce a microenvironment that 
inhibits immune cells. Tumor induced immunosuppres-
sion by transforming growth factor‐β (TGF‐β), a cytokine 
with pleiotropic effects on cell growth and differentia-
tion is known mechanism of immunotherapy resistance. 
We hypothesize that truncating the intracellular domain 
of the TGF‐β receptor will abrogate immunosuppres-
sive signalling through this pathway, which may augment 
immunotherapy effectiveness. Preclinical studies showed 
Fig. 1 Mechanisms tumors use to resist the immune system: 
avoided detection, production of inhibitory microenvironment, death 
resistance
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safety and efficacy of virally transducing T cells with 
TGF‐DNRII and improved proliferation and function 
of T cells. Treatment with TILs engineered to express 
TGF-β DNR and nerve growth factor receptor (NGFR) 
(which is truncated to render it incapable of signalling, 
serves as a control) resulted in best imaging response by 
irRC that was PD/SD/PR in 1/5/1 pts with DCR of 86%. 
All 5 SD patients have had disease reduction of 12–48% 
with responses ongoing. The PR patients continues to 
respond 15  months after therapy. There was no added 
toxicity from the gene modified TIL with toxicities attrib-
uted to lymphodepletion and IL‐2. Genetic modification 
of TIL with TGF‐DNRII is feasible to generate, safe to 
administer and has demonstrated efficacy in malignant 
melanoma. [8].
Loss of the tumor suppressor gene phosphatase and 
tensin homolog (PTEN) inhibits T cell infiltration into 
tumors and has been found to correlate with resistance 
to anti-PD-1 in melanoma patients [33]. We recently 
demonstrated that loss of PTEN impedes trafficking 
of effector T cells to tumors, reduces the sensitivity of 
melanoma cells to T cell mediated killing, and correlates 
with inferior outcomes in patients treated with immune 
checkpoint blockade. Treatment with a selective PI3Kβ 
inhibitor improved the anti-tumor activity of anti-PD-1 
in a genetically engineered PTEN loss tumor model.
Recent studies also identified glycolysis as a candidate 
pathway of resistance. Immuno-resistant PTEN-silenced 
tumors display increased glycolytic activity [34]. Upreg-
ulated expression levels of glycolysis-related genes were 
associated with poor T-cell infiltration in melanoma and 
NSCLC tumor samples. Overexpression of glycolysis-
related enzymes impaired T cell killing of tumor cells, 
whereas inhibition of glycolysis enhanced T cell-medi-
ated antitumor immunity in vitro and in vivo. Inhibition 
of glycolysis enhanced efficacy of adoptive T-cell therapy 
(ACT) and increased glycolytic activity was detected in 
cell lines from melanoma patients non-responding to 
ACT. Reduced expression of IRF1 and CXCL10 immu-
nostimulatory molecules was observed in highly gly-
colytic melanoma cells. These findings indicate that 
increased tumor-intrinsic glycolytic activity is associated 
with poor tumor migration of T cells and reduces sus-
ceptibility of tumors to T cell induced apoptosis. Critical 
role of tumor intrinsic glycolysis in modulating T cell-
mediated antitumor activity may lay foundation for the 
development of glycolysis inhibitors to improve the effec-
tiveness of ACT for cancer treatment.
Tumor mutation burden and liquid biopsies: helpful 
for treatment decisions?
Localized and advanced cancers may generate circu-
lating tumor cells and circulating cell free tumor DNA 
(ctDNA) that can be detected and quantified from 
peripheral blood samples (liquid biopsy). For melanoma 
patients, liquid biopsy results may serve as novel predic-
tive biomarker to guide therapeutic decisions, particu-
larly in the context of mutation-based targeted therapies. 
Tumor mutation burden (TMB) is a potential biomarker 
for immunotherapy response and early measurement 
of circulating tumor ctDNA can help to detect treat-
ment failure to immunotherapy. However, it has not yet 
been clarified how TMB and ctDNA can be used to esti-
mate response to combined CTLA-4 and PD-1 antibody 
therapy in metastatic melanoma. Novel detection tech-
nologies have significantly improved the sensitivity and 
specificity of the ctDNA detection assays as due to the 
low abundance of ctDNA, its detection requires highly 
sensitive and specific techniques. The analysis of ctDNA 
provides three parameters that may be correlated with 
clinical outcome: (1) the total quantity of ctDNA in the 
sample, (2) the molecular fingerprint of the ctDNA by 
mutation detection, and (3) the quantification of mutant 
copy numbers. Three of the most frequently used tech-
niques are digital PCR (dPCR), BEAMing and allele-
specific ligation PCR (LPCR). The clinical implications 
of liquid biopsy in routine diagnostic testing of mela-
noma patients is promising. In a prospective biomarker 
study, 35 melanoma patients treated with ipilimumab 
and nivolumab were assessed using a tumor panel of 710 
tumor-associated genes followed by repeat liquid biop-
sies [35]. Tumor mutational burden (TMB) was higher 
in responders than in non-responders and TMB > 23.1 
Mut/Mb (TMB-high) was associated with a melanoma-
specific survival (MSS) benefit compared to TMB ≤ 23.1 
Mut/Mb (TMB-low or TMB-intermediate). Liquid biop-
sies every 3–4  weeks were taken for analysis of ctDNA 
using targeted gene panel for sequencing. At first follow-
up 3  weeks after treatment initiation, increased ctDNA 
concentration was observed more often in non-respond-
ers and a > 50% decrease in ctDNA was significantly 
associated with response to combined immunotherapy. 
A > 50% increase in ctDNA, or detectable/increasing 
ctDNA at first follow-up were significantly associated 
with worse OS while patients with high TMB showed 
a trend towards prolonged survival. OS was worse in 
patients with TMB ≤ 23.1 Mut/Mb and either ctDNA 
increase/detectable or ctDNA increase of > 50% at first 
follow-up. Liver metastases also had a significant nega-
tive impact on response and there was a trend towards 
lower response rate with elevated lactate dehydrogenase 
(LDH), previous targeted therapy and PD-L1 expression 
< 1%.
Other reports have suggested ctDNA can be predic-
tive of response to anti-PD-1 therapy in metastatic mela-
noma. Longitudinal assessment of ctDNA in 76 patients 
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receiving treatment with PD-1 inhibitors was an accurate 
predictor of response, PFS and OS [36].
The use of liquid biopsy in routine diagnostic test-
ing remains limited due to the following challenges: (1) 
clonal heterogeneity, e.g. the detected ctDNA might not 
represent the predominant tumor clone, thus the pro-
gression of the major clone might be overlooked, (2) not 
defined origin of ctDNA (primary, metastatic, or prema-
lignant lesion; or (3) different cancers developing during 
the course of disease/treatment.
Localized and advanced cancers may also generate 
circulating tumor cells (CTCs) that are detectable in the 
blood. CTCs show promising results in establishing the 
tumor response to chemotherapy and in the prognosis of 
cancer patients. Numerous assays for the direct detection 
of CTCs have been developed that allow for the analysis 
of CTCs at the single-cell stage in the peripheral blood. 
In a study of 84 patients with malignant melanoma, a 
combined analysis of ctDNA and CTCs predicted relapse 
earlier than imaging and was more accurate than serum 
LDH or S100 in a subset of patients [37]. Overall, 32% of 
patients were CTC-positive. An increase in CTC-pos-
itive patients was detected with increased tumor stag-
ing. Analysis of CTCs count and ctDNA < 150 bp appear 
to be promising to predict tumor burden in melanoma 
patients, as negative values may indicate a complete 
remission.
Although the clinical relevance of CTCs and ctDNA for 
disease monitoring in patients with metastatic disease is 
well known and currently entering routine clinical diag-
nostic use, the role of these biomarkers in early-stage 
cancer patients remains to be investigated.
Primary and secondary mechanisms of immunotherapy 
resistance
The immune system has the potential to recognize and 
eliminate tumor cells, and failed immune surveillance 
contributes to cancer development. Many immunothera-
peutics, including checkpoint blockade therapy, harness 
the endogenous antitumor immune response. While clin-
ical benefit can be profound, some patients show primary 
resistance, whereas others experience clinical response 
and then develop secondary resistance. General mecha-
nisms include adaptive evasion, allowing the tumor to 
establish equilibrium with an existing T cell infiltrate, 
and innate evasion, in which T cells and other immune 
cells are excluded from the tumor microenvironment.
Clinical studies have indicated that tumors lack-
ing a baseline infiltrate of activated T cells typically 
fail to respond to checkpoint blockade therapy. For 
T cell-inflamed tumors, multiple mechanisms have 
been implicated in defective T cell-mediated tumor 
elimination. T cells that do effectively home to tumor 
metastases (based on chemokine gradients and acti-
vated vascular endothelial cells) may become dys-
functional, pointing toward immunosuppressive 
mechanisms in the tumor microenvironment. T cell 
anergy due to insufficient B7 co-stimulation, extrinsic 
suppression by regulatory cell populations, inhibition 
by ligands such as programmed death ligand-1 (PD-1), 
metabolic dysregulation by enzymes such as indoleam-
ine-2,3-dioxygenase (IDO), and the action of soluble 
inhibitory factors such as transforming growth factor-β 
(TGF-β) have all been reported to contribute to this 
suppressive microenvironment. This suggests the para-
digm of restoring CD8+ T cells already in the tumor 
through blocking negative regulation.
Gene expression signatures based on the T cell-
inflamed phenotype in the tumor microenvironment 
are associated with the presence of an adaptive immune 
response and clinical benefit from PD-1/PD-L1 blockade 
[38]. This signature was developed on the NanoString 
nCounter gene expression system (NanoString Technolo-
gies, Inc., Seattle, WA) in the context of pembrolizumab 
treatment as a pan-tumor determinant of response to 
PD-1 directed therapy. Samples were obtained at baseline 
from patients undergoing treatment with pembrolizumab 
in clinical trials of multiple distinct tumor types in a rig-
orous stepwise validation of the hypothesis that immune-
related gene signatures can enrich for clinical response to 
PD-1 checkpoint blockade.
Another potential biomarker relevant to a broad spec-
trum of tumors is measurement of total tumor mutation 
burden (TMB). The correlation of TMB and response 
to checkpoint inhibitors was demonstrated in lung can-
cer, which has a broad range of nonsynonymous muta-
tions within the tumor. Overall, tumor types with higher 
median mutation burden tend to be more responsive to 
checkpoint inhibitors than tumors that harbor few muta-
tions. The earliest successes of checkpoint inhibitors 
were in melanomas and non-small cell lung cancers, two 
tumor types that can have high mutation burden due to 
mutagen exposure (UV light and tobacco smoke).
Multiple tumor cell-intrinsic oncogenic events may 
contribute to primary or acquired resistance to immu-
notherapy. The WNT-β-catenin pathway appears to be 
associated with a non-T cell-inflamed TME, as β-catenin-
positive tumors had minimal T cell infiltration and have 
been shown to be more resistant to checkpoint blockade 
therapy. Specifically, tumor cell-intrinsic β-catenin acti-
vation prevents host anti-tumor immune response by 
failure to recruit Batf3-leneage DCs, which are involved 
in both the priming phase and the effector phase of anti-
tumor immune response [39]. Batf3-DCs in the tumor 
microenvironment (TME) are also necessary at the time 
of anti-PD-L1 therapeutic effect. Batf3+ DCs clustering 
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with CD8+ T cells in tumors correlate with a positive 
IFN-γ gene-signature.
Beyond β-catenin, gene deletions and loss-of-function 
mutations of the tumor suppressor phosphatase and 
tensin homolog (PTEN) have also been associated with 
poor T cell infiltration in the tumor microenvironment 
in metastatic melanoma. Loss of PTEN, which leads to 
increased activation of the phosphatidylinositol 3-kinase 
(PI3K)–Akt pathway, has been associated with primary 
and secondary resistance to PD-1 blockade in mela-
noma [40]. Features of T cell-inflamed TME can serve as 
predictive biomarkers for response to anti-PD-1-based 
immunotherapies. Primary resistance to checkpoint 
blockade in most cases is associated with the absence 
of a T cell inflamed TME. Non-T cell-inflamed tumors 
have no shortage of antigens, but lack Batf3-lineage 
DCs. T cell exclusion from the TME can be mediated by 
β-catenin, PTEN loss, and other oncogenic events. Sec-
ondary resistance to immunotherapies can arise upon 
selection for new oncogenic variants that mediate T cell 
exclusion. Two oncogenic events linked to poor T cell 
infiltration and secondary immunotherapy resistance 
are tumor cell-intrinsic β-catenin pathway activation and 
PTEN loss-of-function mutation or deletion.
Next target for immune checkpoint blockade: Tim‑3 
in cancer immunotherapy
Multiple negative immunoregulatory pathways impede T 
cell-mediated tumor destruction in the tumor microenvi-
ronment (TME), contributing to the paradoxical coexist-
ence of TA-specific CD8+ T cells and tumor progression 
in cancer patients. Among them, inhibitory receptors 
(IR) like PD-1 and CTLA-4 play a critical role in damp-
ening T cell functions. Immunotherapies with immune 
checkpoint inhibitors directed against these immunoreg-
ulatory pathways provide long-term clinical benefits to 
patients with a growing range of solid tumors. Exhausted 
T cells upregulate a large number of these receptors, 
including PD-1, CTLA-4, T cell immunoglobulin domain 
and mucin domain containing-3 (Tim-3) also known as 
Hepatitis A virus cellular receptor 2 (HAVCR2), lym-
phocyte activation gene 3 (LAG-3), and T cell tyrosine-
based inhibitory motif domain (TIGIT). These inhibitory 
receptors are expressed by a significant number of tumor 
antigen-specific T cells, with ligands highly expressed in 
the TME. There is evidence of additive/synergistic effects 
on tumor antigen specific CD8+ T cell expansion, sup-
porting the concept of dual blockade through combined 
therapeutic approaches to improve the efficacy of the 
treatment.
Tim-3 is an important negative regulator of innate 
and adaptive immunity. In cancer, PD-1+Tim-3+ CD8+ 
T cells are dysfunctional/exhausted. Notably, TIM-3 
appears to be an adaptive mechanism of resistance to 
PD-1 blockade in mouse lung tumor models. Besides 
CD8 TILs, TIM-3 is also expressed on Tregs and mul-
tiple innate immune cell types, including NK cells and 
APCs. Tim-3+ Fox3+ Tregs, represent a subset of highly 
activated/suppressive Tregs, which also express high-
level PD-1, CTLA-4, and LAG-3. The binding of Tim-3 
to phosphatidylserin promotes the uptake of apoptotic 
cells and cross-presentation of antigen by dendritic cells, 
which constitutively express high-level Tim-3. Multiple 
ligands can bind to Tim-3, including galectin 9, Phos-
phatidylserin, CEACAM-1 and HMGB1. The role of 
these ligands in mediating Tim-3-mediated immunosup-
pression in human cancers remain to be elucidated.
Preclinical data have shown that dual blockade of 
PD-1 and TIM-3 augments tumor antigen-specific 
cell responses in  vitro with evidence of reduced tumor 
growth in  vivo. These data suggest that the PD-1 and 
TIM-3 pathways promote T cell dysfunction in a non-
redundant fashion. They also support that dual blockade 
of PD-1 and TIM-3 reinvigorates effector T cell responses 
more potently than single blockade. In a murine model 
of breast cancer, TIM-3 expression appeared to regulate 
the function of CD103+ DCs through CXCL9 expression 
[41]. Anti-TIM-3 antibody indirectly enhanced a CD8+ 
T cell response during chemotherapy. Anti-TIM-3 or 
anti-galectin 9 antibody increases CXCL9 expression by 
DCs. Therapeutic efficacy was ablated by CXCR3 block-
ade, Batf3 deficiency, or Irf8 deficiency.
Dual blockade of PD-1 and Tim-3 has shown evidence 
of clinical activity with manageable toxicity in PD-1 
refractory NSCLC and melanoma patients [42]. Objective 
responses observed were in PD-L1-positive (TPS ≥ 1%) 
patients, indicating the potential for biomarker enrich-
ment. This combination is being further assessed in sev-
eral clinical trials.
Histopathologic assessment of pre‑ and on‑treatment 
specimens for predicting response to anti‑PD‑(L)1 therapy
Anti-PD-(L)1-based therapies have shown remarkable 
effects in patients with advanced cancers, and may also 
improve outcomes for patients with resectable cancers. 
The neoadjuvant setting also provides a critical window 
for examining pathologic response features within the 
resected tumor. Pathologic response is a possible sur-
rogate for long-term outcomes, and thus examination 
of the definitive resection specimen for residual viable 
tumor (RVT) can potentially be used to predict clinical 
benefit after weeks or months after therapy initiation, 
rather than waiting a years for overall survival data to be 
resulted. As such, it can be used to help guide therapeu-
tic adjustments on both an individual patient-level and 
immunotherapy field-level. Numerous clinical trials for 
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neoadjuvant immunotherapy are underway and many 
of these include assessments of pathologic response 
(e.g. pathologic complete response [pCR], i.e. 0% RVT, 
or major pathologic response [MPR] i.e. ≤ 10% RVT) as 
proposed endpoints. Scoring of pathologic response was 
first developed for neoadjuvant chemotherapy. Chemo-
therapy and immunotherapy have distinct mechanisms 
of action and thus, they have distinct histologic features 
of response, necessitating the development of a new scor-
ing system. To meet that need, Cottrell, et al. developed 
a proposal for immune-related pathologic response cri-
teria (irPRC) using hematoxylin and eosin-stained slides 
from the definitive resection specimens and routine light 
microscopy [43]. Features of immune-mediated tumor 
regression included dense tumor infiltrating lympho-
cytes, foamy macrophages, and tissue repair (neovas-
cularization and proliferative fibrosis), amongst others. 
Specific attention was paid to ensure that the histologic 
areas studied for features of residual viable tumor or evi-
dence of immune-mediated regression were correlated 
with the pre-resection radiographic ‘tumor’ measure-
ments. The proposed irPRC was then tested for inter-
observer reproducibility amongst 5 pathologists and 
showed very high reproducibility at 10% intervals of 
residual viable tumor with an interclass coefficient > 0.9 
[43]. Similar histologic features have since been reported 
in specimens from patients with melanoma and many 
other solid tumor types that were treated with anti-PD-1-
based therapies in the neoadjuvant setting [43]. The main 
goal in the development of such a histology based scoring 
system is to predict long-term survival after only a few 
weeks on therapy. The data in the neoadjuvant setting 
is not yet mature enough to correlate the observed his-
tologic features with 5 year patient outcomes. However, 
these same histologic features are observed in immune-
mediated tumor regression in patients with advanced 
disease treated with anti-PD-1 based therapy, where data 
on long-term follow up is available. To test the associa-
tion of these features with survival, irRPC was used to 
score pathologic response in early on-treatment biopsy 
specimens (taken 2–4  weeks after therapy initiation) 
from patients with melanoma. Patients with a major 
pathologic response on biopsy (MPRbx; < 10% residual 
viable tumor) showed significantly improved 5-year over-
all survival, compared to those with a larger proportion 
of RVT [43] (Fig.  2) Ongoing analyses include in-depth 
assessment of individual histologic features observed in 
these hematoxylin and eosin-stained specimens, as well 
as clinically meaningful thresholds of RVT beyond pCR/
MPR in on-treatment specimens. Taken together, these 
findings lend support to the idea that irPRC will be pre-
dictive of OS in the neoadjuvant setting. They also sug-
gest that early on-treatment H&E biopsies for patients 
advanced setting may have clinical utility in indicating a 
response to therapy, weeks before radiographic evidence 
is present.
Session—emergent strategies
Promising treatment strategies in early development
Interleukin-1 (IL-1) has been known to be a key media-
tor of immunity and inflammation. Its dysregulation has 
been implicated in tumorigenesis and tumor progres-
sion, and its upregulation is thought to be associated 
with many tumors. Overexpression of the IL-1 agonists 
Fig. 2 Major pathologic response assessed on biopsy, rather than definitive surgical resection
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IL-1a and IL-1b has been shown to promote tumor inva-
siveness and metastasis by inducing the expression of 
angiogenic genes and growth factors. Tumor IL-1 sign-
aling is also involved in resistance to immunotherapy 
and immune evasion with robust evidence in NSCLC 
and pancreatic cancer. IL-1 receptor accessory protein 
(IL1RAP) is required to activate IL-1 receptor signal-
ing. IL1RAP is expressed in several solid tumors, both 
on cancer cells and tumor-associated inflammatory cells. 
IL-1β blockade with canakinumab significantly reduced 
incidence of lung cancer in the CANTOS trial [44]. 
CAN04 (nidanilimab) is a humanized IgG1 monoclonal 
antibody targeting IL1RAP, blocking IL-1α and β signal-
ing and triggering antibody-dependent cellular cytotoxic-
ity (ADCC). Preclinical data in a NSCLC patient-derived 
xenograft model showed synergistic effects between 
CAN04 and cisplatin/gemcitabine. In a phase IIa trial, 
CAN04 was well tolerated with infusion-related reac-
tions the most frequent adverse event in patients with 
various solid tumors [45]. A recommended phase 2 dose 
of 10 mg/kg was established. The dose expansion phase 
of the trial will evaluate CAN04 as monotherapy as well 
as in combination with cisplatin/gemcitabine in NSCLC 
and gemcitabine/nab-paclitaxel in pancreatic ductal 
adenocarcinoma.
The STING pathway senses intracellular DNA, trig-
gering an immediate production of type I IFN. STING 
activation has wide-ranging impact on both the innate 
and adaptive immune response by inducing  antigen-
presenting cell recruitment and priming CD8+ T cells 
against tumor antigens. MIW815 (ADU-S100) is a syn-
thetic cyclic dinucleotide (CDN), a first-in-class STING 
agonist. MIW815 (ADU-S100) has shown efficacy in 
combination with PD-1 checkpoint inhibitors and elic-
ited near complete clearance of injected and non-injected 
tumors in mice. In a phase 1b combination trial of intra-
tumorally administered MIW815, a novel synthetic cyclic 
dinucleotide that activates the STING pathway, and spar-
talizumab, a humanized IgG4 monoclonal antibody that 
blocks the binding of PD-1 to PD-L1/2 [46]. Data from 
83 patients with advanced/metastatic solid tumors or 
lymphoma were evaluated. The most common primary 
diagnoses were melanoma (42.2%) and triple-negative 
breast cancer (13.3%). Most patients (72.3%) received 
prior immunotherapy. No dose-limiting toxicities were 
reported in any of the dosing cohorts and adverse events 
with the combination were no more frequent or severe 
than those reported with either single-agent. Systemic 
IFN-β levels appeared to increase in a dose-dependent 
manner and a trend was observed between IFN-β levels 
and systemic exposure. Other cytokines detected (IP-10, 
MCP-1, and IL-6) did not demonstrate significant dose 
dependency and/or PK/PD relationships. CD8 frequency 
as detected by IHC increased in responding patients with 
high PD-L1 at baseline. The combination of MIW815 
and spartalizumab demonstrated antitumor activity in 
PD-1-naïve patients with TNBC and patients with anti 
PD-1-relapsed/refractory melanoma. Five patients in 
the MIW815 weekly-dose cohort achieved confirmed 
responses, including one complete response. Three 
of these responses, including the complete response, 
occurred among patients with immunotherapy-naive 
triple-negative breast cancer, two of whom had PD-L1 
expression greater than 1% at baseline. The other two 
responders had previously received immunotherapy. 
These findings are promising as the combination was 
well-tolerated, with no dose-limiting toxicities reported 
to date and demonstrated anti-tumor activity.
Adjuvant therapy for high‑risk melanoma—current status
Most patients with stage III (lymph node positive) mela-
noma are offered adjuvant therapy, although if only one 
node is involved with very small amounts of melanoma 
(< 1  mm) some centers elect observation. Ipilimumab 
was the first successful checkpoint inhibitor in metastatic 
melanoma and has also been shown to be effective in the 
adjuvant setting. However, adjuvant treatment with ipili-
mumab is associated with significant toxicity, especially 
since the adjuvant dose is three-fold higher than the 
metastatic dose. The toxicity of ipilimumab indicates that 
nivolumab and pembrolizumab may be preferred as adju-
vant treatment. In the CheckMate-238 trial, the 1-year 
rate of RFS was 70.5% with nivolumab versus 60.8% 
with ipilimumab (HR for disease recurrence or death, 
0.65; 97.56% CI 0.51–0.83; P < 0.001) [7]. Treatment-
related grade 3–4 adverse events were reported in 14% 
of patients treated with nivolumab versus 46% of patients 
treated with ipilimumab. Similarly, pembrolizumab sig-
nificantly increased 1-year rate of RFS versus placebo 
(HR for recurrence or death, 0.57; 98.4% CI 0.43–0.74; 
P < 0.001) with 15% of pembrolizumab patients expe-
riencing treatment-related grade 3–5 adverse events 
[6]. Targeted therapy with BRAF/MEK inhibitor com-
binations are also effective as adjuvant therapy, with an 
estimated three-year RFS rate of 58% observed with dab-
rafenib plus trametinib versus 39% with placebo (HR for 
relapse or death, 0.47; 95% CI 0.39–0.58; P < 0.001), and 
so represent a new standard of care for BRAF-positive 
patients.
Immunotherapy with anti-PD-1 agents is effective in 
adjuvant therapy for all high-risk melanoma patients 
while BRAF/MEK targeted therapy is effective for high-
risk patients with BRAF mutation. Present clinical trial-
based evidence suggests that both targeted agents and 
anti-PD-1 agents derive clinical benefit and a tolerable 
profile in the adjuvant setting in BRAF-mutant patients. 
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However, there is no long-term (> 4 years) head-to-head 
comparison. Targeted agents involve daily oral admin-
istration versus IV infusion every 2–4  weeks with anti-
PD-1 therapy. Toxicity with BRAF/MEK inhibitors 
can be chronic but manageable and can be reversed by 
treatment interruption, while toxicity with anti-PD-1s 
is uncommon but can be severe and may not always be 
reversible.
Findings from ongoing adjuvant trials are eagerly antic-
ipated. These include two US Intergroup studies, the 
E1609 trial of ipilimumab 3 or 10 mg/kg versus high-dose 
IFN and the S1404 trial of pembrolizumab versus high-
dose IFN or ipilimumab 10  mg/kg, and the CheckMate 
915 trial of combined nivolumab plus ipilimumab versus 
nivolumab monotherapy. Several clinical trials are ongo-
ing, using nivolumab and pembrolizumab in monother-
apy or in combination with chemotherapy, radiotherapy, 
other immunotherapies, and targeted therapies. Depend-
ing on the molecular features of the patients and tumors, 
as well as the responses to therapy, personalized treat-
ment should be considered for melanoma patients, in 
order to achieve better clinical benefits. Further research 
is necessary to explore oncogenic pathways and the TME 
potential in the treatment of melanomas.
Neoadjuvant immunotherapy—the pathway to therapy 
personalization
Locally/regionally advanced melanoma confers a major 
challenge in terms of surgical and medical management. 
Surgical treatment carries the risks of surgical morbidi-
ties and potential complications that could be lasting. In 
addition, these patients continue to have a high risk of 
relapse and death despite the use of standard adjuvant 
therapy. Neoadjuvant therapy has the potential to sig-
nificantly improve the clinical outcome of these patients, 
particularly in this era of newer and effective targeted 
and immunotherapeutic agents. Several neoadjuvant tar-
geted and immunotherapy studies have been completed 
in melanoma to date and have yielded promising clinical 
activity.
Potential benefits of neoadjuvant immunotherapy 
include reduction in tumor burden before surgery with 
improvements in surgical resectability, organ preser-
vation, and improvement in overall survival (OS). In 
addition, pathological response evaluation can serve as 
surrogate outcome markers for RFS and OS in addition 
to clinical and radiologic responses, and stronger and 
broader tumor-specific T cell responses may be induced. 
Nonresponding patients however may deteriorate before 
potential curative surgery, which might also be impaired 
by immune-related adverse events.
Neoadjuvant studies provide access to blood and 
tumor biospecimens before and during systemic therapy, 
supporting studies of immunologic and histologic corre-
lates of tumor response. Such studies can allow for bet-
ter understanding of the antitumor mechanisms of action 
and ultimately would enable more selective application 
of therapeutic agents to patients who are more likely to 
benefit.
In the OpACIN study, neoadjuvant ipili-
mumab plus nivolumab did not delay surgery and the 
pathologic response rate was high (78%) but treatment 
was highly toxic with 90% grade 3–4 adverse events. Also, 
higher frequency of tumor resident T cell receptor (TCR) 
clones was observed in neoadjuvant treated tumors [47]. 
In the phase II OpACIN-neo trial to identify the opti-
mal neoadjuvant combination scheme of ipilimumab 
and nivolumab, two cycles of ipilimumab 1  mg/kg plus 
nivolumab 3  mg/kg was tolerated and induced a patho-
logical response in a high proportion of patients [48].
In a pooled analysis from the International Neoad-
juvant Melanoma Consortium (INMC), neoadjuvant 
immunotherapy and targeted therapy showed efficacy in 
resectable clinical stage III melanoma patients and were 
associated with high pCR rate [19].
In both the OpACIN and OpACIN-neo trials, no 
patients with a pathologic response had relapsed after 
a median follow-up of 30 and 8.3  months, respectively. 
In stage IV melanoma, long-term benefit is observed in 
patients achieving CRs with immune checkpoint inhi-
bition, even after cessation of therapy. This raises the 
question of whether complete lymph node dissection 
(CLND) can be omitted when a complete pathologic 
response with neoadjuvant immunotherapy is achieved. 
The aim of the phase II PRADO study is to confirm the 
pathological response rate and toxicity of neoadjuvant 
ipilimumab plus nivolumab. Additional aim is to deter-
mine subsequent therapy i.e. omitting surgery and adju-
vant nivolumab based on the pathological response. The 
pathologic response in the largest lymph node can be 
considered a reliable indicator of therapeutic response 
to neoadjuvant immunotherapy in patients with stage III 
melanoma [49]. To date, the PRADO trial demonstrated 
that pre-treatment biomarker analysis in index lymph 
node as well as pathologic evaluation of the marked 
lymph node is feasible.
These results describe the feasibility of neoadjuvant 
immune checkpoint blockade in melanoma demonstrat-
ing that neoadjuvant immunotherapy may be superior 
to adjuvant immunotherapy. However, neoadjuvant may 
not offer benefit over adjuvant therapies to all patients 
because it induced high toxicity rates; therefore, it needs 
to be further investigated to balance efficacy and toxicity. 
Immune correlates of response were identified, demon-
strating higher lymphoid infiltrates in responders. Per-
sonalization of neoadjuvant immunotherapy based on 
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DNA/RNA signatures and personalization of surgical 
extent may become a standard.
What combinations are really worth it?
Nivolumab plus ipilimumab show a sustained long-term 
benefit with 5-year OS of 52% in the CheckMate 067 
trial, compared to 44% with nivolumab and 26% with ipil-
imumab [50]. Even after discontinuation, many patients 
may continue to derive benefit from combination 
nivolumab plus ipilimumab, with similar outcomes for 
patients who discontinued treatment because of toxicity 
during the induction phase and those who did not [50, 
51]. The effect of the combination has also been explored 
using a novel endpoint of treatment-free survival (TFS), 
defined as the area between Kaplan–Meier curves for 
time to immune checkpoint inhibitor protocol therapy 
cessation and time to subsequent systemic therapy initia-
tion or death, partitioned as time with and without tox-
icity [52]. This revealed a long PFS without toxicity after 
treatment cessation for patients who received nivolumab 
plus ipilimumab. Given the uncertainty of the benefit 
of repeated dosing of nivolumab plus ipilimumab, a de-
escalation study of dropping ipilimumab after two doses 
of nivolumab plus ipilimumab for selected patients is 
being investigated (NCT03122522).
In another trial, two different combination dose regi-
mens were assessed and showed a significantly lower 
incidence of treatment-related grade 3–5 adverse events 
with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg com-
pared with the approved doses of nivolumab 1  mg/kg 
plus ipilimumab 3  mg/kg [53]. No difference in PFS or 
OS was observed between groups, although the study 
was not powered to determine whether there was an effi-
cacy difference between these two arms.
Nivolumab plus ipilimumab is also very effective in 
melanoma patients with brain metastases, with durable 
intracranial responses achieved by 51% of patients with 
asymptomatic brain metastases with no prior local brain 
therapy [54]. Two-year intracranial PFS was 49% and 
2-year OS was 63%. The combination may also have a 
role as adjuvant therapy in patients with surgically resect-
able or completely irradiated stage IV disease. In the 
phase II IMMUNED trial in stage IV melanoma patients 
with resected or completely irradiated melanoma, adju-
vant therapy with nivolumab alone or in combination 
with ipilimumab resulted in improved RFS compared 
placebo [55]. The rate of grade 3–4 treatment-related 
adverse event was higher than reported in the Check-
Mate 067 trial in patients with metastatic disease, but 
no treatment-related deaths had occurred. However, the 
combination of nivolumab plus ipilimumab may not be 
better than nivolumab monotherapy as adjuvant therapy 
for stage III resectable disease (https ://news.bms.com/
press -relea se/corpo ratef inanc ial-news/brist ol-myers 
-squib b-annou nces-updat e-check mate-915-opdiv o-niv).
Therapeutic targets in non‑T cell‑inflamed tumors
Responses to immunotherapy preferentially occur in 
tumors with a pre-existing antitumor T-cell response 
that can be measured by expression of DC and CD8+ 
T cell-associated genes. The tumor subset with this sig-
nature has been described as the T cell-inflamed phe-
notype. Understanding mechanisms of resistance in 
non-inflamed tumors will help address treatment failure 
and increase the proportion of patients responding to 
immunotherapy.
Intrinsic β-catenin signaling contributes to a lack of 
T-cell infiltration in melanoma. β-catenin represses 
CCL4, leading to lack of Batf3+ DC recruitment, failed T 
cell priming, and lack of response to checkpoint blockade. 
There is an inverse correlation between WNT/β-catenin 
and T cell-inflamed signature using transcriptional analy-
sis across tumor types [56]. Gene expression signatures 
associate with resistance to immune-checkpoint inhibi-
tion and mutations associated with T cell-inflamed or 
non-T cell-inflamed phenotypes have been clinically 
validated. For example, one gene signature, the Tumor 
Inflammation Signature (TIS), has been developed as a 
clinical-grade assay that provides both quantitative and 
qualitative information about the immune environment 
within a tumor, reporting on the presence of an immune 
infiltrate as well as the functional status of T cells. The 
TIS, developed on the NanoString  nCounter® gene 
expression system (NanoString Technologies, Inc., Seat-
tle, WA, USA), is an 18-gene signature that measures the 
status of adaptive immune response within the tumor. 
The TIS contains IFN-γ-responsive genes related to anti-
gen presentation, chemokine expression, cytotoxic activ-
ity, and adaptive immune resistance.
Tumor mutation load or tumor mutation burden 
(TMB), measured by comprehensive genomic profiling, 
is an important emerging biomarker that shows promise 
in its ability to predict the response to immune check-
point inhibitors. TMB is a measure of the number of 
mutations within a tumor genome, defined as the total 
number of mutations per coding regions. There is large 
variability in TMB within tumor types, ranging from just 
a few to thousands of mutations. A high TMB load has 
been shown to be associated with better response rates to 
checkpoint inhibitors in melanoma, NSCLC, and urothe-
lial carcinoma. Limited responses to anti-PD-1 and 
anti-PD-L1 agents are associated with tumor types exhib-
iting low TMB such as colorectal, ovarian, and prostate 
tumors.
Targeting of these mutations or pathways may present 
rational immunotherapy combination approaches to 
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overcome non-T cell-inflamed tumors or augment immu-
notherapy in T cell-inflamed tumors and multiple clini-
cal trials are being planned and initiated. For example, 
mutations in the isocitrate dehydrogenase (IDH)-1 and 
IDH2 genes may facilitate escape from immune surveil-
lance in a subset of malignant gliomas. Reduced expres-
sion of CTLA genes and IFN-γ-inducible chemokines 
has been shown in IDH-mutated tumors. Treatment with 
IDH-C35, a selective mutant IDH-1 inhibitor, restored 
chemokine expression, promoted T-cell infiltration, and 
increased the efficacy of therapeutic peptide vaccination 
against IDH-mutated gliomas in mice [57]. The combina-
tion of an IDH1 inhibitor (ivosidenib) plus nivolumab is 
now being investigated in a phase II study in patients with 
IDH1-mutant advanced solid tumors. Novel clinical-
grade biomarkers are needed to guide the choice of the 
immunotherapy agents and combinations to obtain the 
maximal likelihood of patient benefit. Translational end-
points include changes in IFN-associated gene expres-
sion, epigenetic and metabolomics changes in tumor and 
tumor infiltrating and peripheral blood immune cells and 
ctDNA.
Novel circulating biomarkers in melanoma
Predictive biomarkers are needed to help optimally select 
patients for adjuvant therapy or treatment of metastatic 
disease, to monitor response and recurrence, to better 
understand mechanisms of resistance, and to identify 
patients at risk of severe toxicity. Biomarkers study can 
be used to help develop next generation immunotherapy 
agents and combinations treatments for melanoma. In 
biomarker enrichment (Fig.  3a), tissue or blood assays 
can be used to identify immuno-responsive patients (e.g. 
based on PD-L1 status) and non-responsive patients, 
who may be enrolled into trials based on biomarker sta-
tus. Biomarker-directed escalation (Fig. 3b) involves per-
forming assays after initiation of immunotherapy in order 
to identify which patients are responsive and should con-
tinue therapy and which do not respond and may need 
therapy escalated.
Fig. 3  Biomarker enrichment and biomarker-driven escalation. a Biomarker enrichment (current strategy—PD-L1 in NSCLC). b Biomarker-directed 
escalation
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Whole plasma and exosome proteomic profiling may 
be used to develop a predictive model of immunother-
apy response and toxicity, and to obtain insight into the 
mechanisms underlying immunotherapy resistance. In 
a cohort of 150 melanoma patients receiving anti-PD-1 
antibodies whole plasma was analyzed at baseline, and 
on-treatment at 6-week and 6-month timepoints [58]. 
Proteomic analysis in plasma was performed using a 
multiplex proximity extension-based assay that ena-
bled simultaneous detection of more than 1000 proteins 
including cytokines, chemokines and growth factors. 
Patients who responded to immunotherapy vs those 
who did not respond had differentially expressed pro-
teins at baseline, including interleukin (IL) 33 receptor 
(ST2), IL-6, CCL13 and stem cell factor (SCF) that were 
predictive of OS and progression-free survival (PFS). 
Whereas high baseline and on-treatment levels of IL-6 
have been associated with worse survival in clinical trials 
of nivolumab alone or in combination with ipilimumab 
[31, 59]. Considering the biomarker-directed escalation, 
70 differentially expressed cytokines and chemokines 
were identified between baseline and on-treatment 
time-points, the majority of which were reflective of 
immune activation. In addition, many more differentially 
expressed proteins were identified between responders 
and non-responders at 6 weeks than at baseline. Several 
6-week differentially expressed proteins were predictive 
of survival (e.g. Inducible T Cell Costimulatory Ligand 
(ICOSLG), IL-8 and MIA). However, it is too early to 
consider using these biomarkers in escalation trials and 
further validation is ongoing.
Conclusions
Recent insights into genetic and phenotypic characteri-
zation of specimens from patients with melanoma have 
initiated a new era of rapidly evolving treatments. The 
use of novel immunotherapies, especially immune check-
point inhibitors including CTLA-4, PD-1 and others, as 
well as targeted BRAF and MEK inhibitors have signifi-
cantly improved outcomes for many patients with meta-
static melanoma. However, despite these improvements, 
most patients still either fail to respond or will relapse 
over time. There is a need to increase the ratio of patients 
who benefit from the major advances in therapy vs those 
who did not benefit. Better understanding of the TME 
and host immune response may lead to development of 
biomarkers that help identify patients for the best treat-
ment option, as well as new treatments and new com-
bination strategies. Increased use of these new systemic 
treatments in the neoadjuvant and adjuvant settings may 
also help improve long-term outcomes for patients.
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